155 related articles for article (PubMed ID: 6715088)
1. Effect of procetofen on serum lipids and apoproteins.
Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L
Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088
[TBL] [Abstract][Full Text] [Related]
2. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
Canzler H; Bojanovski D
Artery; 1980; 8(2):171-8. PubMed ID: 7458684
[TBL] [Abstract][Full Text] [Related]
3. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.
Micheli H; Pometta D; Gustafson A
Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):503-6. PubMed ID: 528097
[TBL] [Abstract][Full Text] [Related]
5. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
[TBL] [Abstract][Full Text] [Related]
6. Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia.
Viikari J; Solakivi-Jaakkola T; Lehtonen A
Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):362-5. PubMed ID: 6811447
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Sznajderman M
Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
[No Abstract] [Full Text] [Related]
8. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Lehtonen A; Viikari J
Artery; 1982; 10(5):353-67. PubMed ID: 7181678
[TBL] [Abstract][Full Text] [Related]
10. The effect of etofibrate retard, bezafibrate and procetofen.
Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
Artery; 1980; 8(2):128-33. PubMed ID: 7458677
[TBL] [Abstract][Full Text] [Related]
11. [Effect of procetofen on lipoproteins and blood lipids in patients with hyperlipemia].
Abaurre R; Vega J; Maneschi E; Bernabe H
Medicina (B Aires); 1980; 40(6 Pt 2):896. PubMed ID: 7219169
[No Abstract] [Full Text] [Related]
12. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
[No Abstract] [Full Text] [Related]
13. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
14. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
[No Abstract] [Full Text] [Related]
15. [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
Zeman M; Zák A; Tvrzická E; Konárková M; Stípek S
Cas Lek Cesk; 2002 Apr; 141(7):211-6. PubMed ID: 12053756
[TBL] [Abstract][Full Text] [Related]
16. [Modification of serum lipids, lipoproteins and apoproteins AI and B in patients with hyperlipidemia Type IIa and IIb using polyenylphosphatidylcholine].
Noseda G; Suvà F; Fragiacomo C
Schweiz Med Wochenschr; 1985 Jul; 115(30):1064-70. PubMed ID: 4035328
[TBL] [Abstract][Full Text] [Related]
17. Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate.
Plancke MO; Olivier P; Clavey V; Marzin D; Fruchart JC
Methods Find Exp Clin Pharmacol; 1988 Sep; 10(9):575-9. PubMed ID: 3226223
[TBL] [Abstract][Full Text] [Related]
18. [Effect of the PSMF diet on plasma lipids and lipoproteins in obese subjects].
Petrillo A; Chevaux F; Rohrer J; Darioli R
Schweiz Med Wochenschr; 1984 Dec; 114(49):1837-41. PubMed ID: 6515380
[TBL] [Abstract][Full Text] [Related]
19. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Micheli H; Pometta D; Gustafson A
Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
